Related Experiment Video
Updated: Aug 5, 2026
07:40
Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
Published on: January 12, 2022
An Aggregation-Induced Polymerization Poly(Disulfide)-Drug Nanoplatform for Autoimmune Uveitis Therapy via Inhibiting
Yuelan Wu1, Wenbo Geng1, Qinjin Dai1
1Ophthalmology Medical Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory For the Prevention and Treatment of Major Blinding Eye Diseases, Chongqing Branch (Municipality Division) of National Clinical Research Centre For Ocular Diseases, Chongqing, China.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|July 29, 2026
Summary
A novel nanoplatform effectively delivers drugs to the eye, inhibiting the cGAS-STING pathway to treat autoimmune uveitis by scavenging cell-free DNA and reducing inflammation.
Area of Science:
- Ophthalmology
- Immunology
- Nanomedicine
Background:
- Autoimmune uveitis is a severe inflammatory eye condition.
- The cGAS-STING pathway amplifies inflammation by detecting cell-free DNA (cfDNA).
- Current treatments face challenges with drug delivery across the blood-retinal barrier and controlling complex inflammation.
Purpose of the Study:
- To develop a nanoplatform for enhanced intraocular drug delivery.
- To synergistically inhibit the cGAS-STING pathway and manage autoimmune uveitis.
- To overcome limitations of conventional therapies in penetrating the blood-retinal barrier.
Main Methods:
- Created a cationic poly(disulfide)-drug nanoplatform (LA/DexP) via self-assembly.
- Utilized electrostatic interactions for cfDNA scavenging and thiol-disulfide exchange for enhanced barrier penetration.
- Evaluated the nanoplatform in an experimental autoimmune uveitis mouse model.
Main Results:
- LA/DexP efficiently scavenged cfDNA, inhibiting cGAS-STING pathway overactivation.
- Achieved significantly enhanced blood-retinal barrier penetration compared to free dexamethasone phosphate.
- Demonstrated reduction in uveitis severity, pro-inflammatory cytokines, and immune cell imbalance.
Conclusions:
- The developed nanoplatform offers superior intraocular drug delivery and cGAS-STING pathway inhibition.
- LA/DexP effectively treats autoimmune uveitis by modulating inflammatory responses.
- This strategy presents a promising therapeutic approach for sight-threatening inflammatory eye diseases.
